Common autoimmune drugs reduce mortality, up clinical status in COVID-19: NIH
By
Alicia Lasek (f3)
Jun 06, 2022
Two commonly used autoimmune drugs could be used in addition to standard-of-care treatments to improve COVID-19 outcomes, the agency says.
Burden of persistent symptoms high after COVID-19 infection
May 24, 2022
– A high burden of persistent symptoms is observed in persons after COVID-19, but no specific causes of symptoms of postacute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV2)...
CDC: Turn to Paxlovid to treat COVID-19, not steroids or antibiotics
By
Alicia Lasek (f3)
Apr 26, 2022
The agency is urging clinicians to consider the now readily available, recommended therapies such as Paxlovid as first-line COVID-19 treatments.
Skilled nursing’s bigger COVID killer
By
James M. Berklan
Feb 25, 2022
Perhaps I shouldn’t have been surprised about some of the latest news about COVID and its effects on the skilled nursing sector. But I was. And you can be sure there’s more to come in the future.
NIH panel updates treatment guidelines for non-hospitalized COVID-19 patients
By
Alicia Lasek
Jan 25, 2022
A new recommended treatments list addresses the omicron variant’s current dominance and drug supply shortages.
COVID-19 rapid test makers struggling to meet demand
Jan 21, 2022
However, government’s order for the free test kits is in addition to existing supply and does not interfere with existing orders
Pfizer says final data show COVID-19 pill stays strong against severe illness
Dec 14, 2021
Latest results show that drug cuts hospitalizations, deaths by nearly 90 percent when taken within three to five days of the start of symptoms
Back to before census
By
Steven Littlehale
Dec 10, 2021
One of my favorite lyrics from the musical “Ragtime” is “We can never go back to before.” The character Mother sings about no longer being a slave to societal expectations; she is confident, moving...
Best bet against omicron? Prior infection or a booster shot, early research suggests
By
Alicia Lasek
Dec 09, 2021
A two-dose course of the Pfizer-BioNTech COVID-19 vaccine may not be enough to effectively combat the new omicron coronavirus variant, but a booster shot may do the trick, two early lab studies suggest....
Two years into pandemic, we’re better prepared to fight off virus variants
By
Alicia Lasek
Dec 02, 2021
Despite the threat of the quickly spreading and highly mutated omicron coronavirus variant — which has just landed in the U.S. — we are safer than we were before the pandemic, some experts say.